BioAtla, Inc. (BCAB) Research

BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.

Market snapshot

Symbol
BCAB
Price
$3.66
Day change
+2.96%
Market cap
$4.6M
P/E ratio
-0.11x
52-week range
3.12-71.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$250

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Celularity Inc. (CELU)
  • Evaxion Biotech A/S (EVAX)
  • Generation Bio Co. (GBIO)
  • Mersana Therapeutics, Inc. (MRSN)
  • Mural Oncology plc (MURA)
  • PolyPid Ltd. (PYPD)

Recent insider activity

  • Vasquez Christian — F-InKind (175 shares) on 2026-03-11
  • Vasquez Christian — F-InKind (82 shares) on 2026-05-31
  • SHORT JAY M PHD — F-InKind (639 shares) on 2026-03-12
  • SHORT JAY M PHD — F-InKind (259 shares) on 2026-05-31
  • Sievers Eric — F-InKind (134 shares) on 2026-05-31

Open BioAtla, Inc. (BCAB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.